Aripiprazole in autism spectrum disorders and fragile X syndrome

Craig A. Erickson, Kimberly A. Stigler, David J. Posey, Christopher J. McDougle

Research output: Contribution to journalArticle

39 Scopus citations


Autism spectrum disorders (ASDs) are childhood onset developmental disorders characterized by impairment of social skills and repetitive behavior, and also for classic autistic disorder, a significant impairment of communication. In addition to these core symptom domains, persons with ASDs frequently exhibit interfering behavioral symptoms, including irritability marked by aggression, self-injurious behavior, and severe tantrums. Aripiprazole is an atypical or newer generation antipsychotic with a unique mechanism of action impacting dopaminergic and serotonergic neurotransmission. The drug has been found efficacious for several indications, including most recently for use targeting irritability associated with autistic disorder in youth. Fragile X syndrome is the most common inherited cause of developmental disability and the most common known single gene cause of ASDs. As in idiopathic ASDs, irritable behavior is often exhibited by persons with fragile X syndrome. However, research to date in this disorder has not focused on this target symptom cluster. An initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with fragile X syndrome.

Original languageEnglish (US)
Pages (from-to)258-263
Number of pages6
Issue number3
StatePublished - Jul 2010


  • Aripiprazole
  • Autistic disorder
  • Fragile X syndrome
  • Irritability

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Pharmacology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Aripiprazole in autism spectrum disorders and fragile X syndrome'. Together they form a unique fingerprint.

  • Cite this

    Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010). Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics, 7(3), 258-263.